Exenatide once weekly for the treatment of type 2 diabetes
The DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index.
Abstract
Exenatide is the first glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes mellitus (T2DM). Exenatide lowers blood glucose through multiple mechanisms, including enhancement of glucose-dependent insulin secretion, suppression of excess glucagon secretion, reduction of food intake and slowing of gastric emptying. The current formulation of exenatide requires twice-daily dosing (exenatide BID), and an extended-release formulation of exenatide is now in development for use as a once-weekly injection (exenatide QW). The purpose of this report is to review the most current clinical data on the development of exenatide QW for the treatment of T2DM. In clinical trials, exenatide QW significantly improved glycemic control, resulted in patient weight loss, and was well tolerated in patients with T2DM. In a head-to-head clinical trial, exenatide QW caused greater improvements in glycemic control and was better tolerated than exenatide BID. Given the rapidly increasing prevalence of diabetes and obesity worldwide, exenatide QW is a promising development candidate for the treatment of T2DM.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Once-weekly treatment with EX-LAR (considering the potential beneficial effects of GLP-1R activation on β cells and weight loss associated with many patients) is a promising potential strategy for diabetes prevention. Similarly, once-weekly EX-LAR preparation can be used as an anti-obesity treatment in patients without T2DM or impaired glucose tolerance (118).”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [118]
Citations
Cites
Wild, S., Roglic, G., Green, A., Sicree, R., & King, H. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1047 · Cited by 15,297
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
The Pathobiology of Diabetic Complications
Brownlee, M. (2005) · Diabetes · doi:10.2337/diabetes.54.6.1615 · Cited by 5,339
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 1×
“Incretins are intestinally derived hormones that are released in response to food intake and have important effects on glucose homeostasis [13] .”
BackgroundKahn, S. E. (2003) · Diabetologia · doi:10.1007/s00125-002-1009-0 · Cited by 2,166
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · cited 4×
“These studies, performed in T2DM patients, demonstrated that 10 μg of exenatide BID, either as monotherapy or added in combination with a variety of traditional oral therapies (metformin, sulfonylureas, and/or TZDs), was associated with HbA1c reductions of approximately -1% and body-weight reductions averaging -2 to -…”
BackgroundInfluentialGlucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402 · cited 1×
“GLP-1 is known to enhance glucose-dependent insulin secretion, improve glucose-dependent suppression of inappropriately high glucagon secretion, slow gastric emptying, and reduce food intake [16-18] in humans.”
Background
Research works printed but not linked: 3
- Ratner RE Rosenstock J Boka G. A dose-finding study of the new GLP-1 agonist AVE0010 in type 2 diabetes insufficiently controlled with metformin. Diabetes 2008;57:A129 [Abstract 433-P]
- Balena R Ratner R Berria R et al. Eight weeks of treatment with the long acting human GLP-1 analogue R1583 improves glycemic control and lowers body weight in subjects with type 2 diabetes mellitus (T2DM) treated with metformin: A double-blind placebo-controlled phase 2 study. Diabetes 2008;57:A33 [abstract 108-OR]
- Diabetes Atlas. Third edition©. International Diabetes Foundation 2006
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
“56,57 Furthermore, there is a focus on developing GLP-1RAs that can be taken orally without the need for injections.”
Venoms as a platform for human drugs: translating toxins into therapeutics
King, G. F. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.621940 · Cited by 516
Graaf, C. D., Donnelly, D., Wootten, D., Lau, J., Sexton, P. M., Miller, L. J., Ahn, J.-M., Liao, J., Fletcher, M. M., Yang, D., et al. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011395 · Cited by 403
GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
Wang, J.-Y., Wang, Q.-W., Yang, X.-Y., Yang, W., Li, D.-R., Jin, J.-Y., Zhang, H.-C., & Zhang, X.-F. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1085799 · Cited by 248
“Similarly, once-weekly EX-LAR preparation can be used as an anti-obesity treatment in patients without T2DM or impaired glucose tolerance (118).”
BackgroundMadsbad, S., Kielgast, U., Asmar, M., Deacon, C. F., Torekov, S. S., & Holst, J. J. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01357.x · Cited by 202
Venomics: a new paradigm for natural products-based drug discovery
Vetter, I., Davis, J. L., Rash, L. D., Anangi, R., Mobli, M., Alewood, P. F., Lewis, R. J., & King, G. F. (2011) · Amino Acids · doi:10.1007/s00726-010-0516-4 · Cited by 197
Animal toxins — Nature’s evolutionary-refined toolkit for basic research and drug discovery
Herzig, V., Cristofori-Armstrong, B., Israel, M. R., Nixon, S. A., Vetter, I., & King, G. F. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114096 · Cited by 181
“In order to improve patient acceptance and compliance, a new formulation was developed in which the peptide is embedded in biodegradable polymeric microspheres that extends the duration of exenatide release to such an extent that therapeutic levels can be maintained with weekly injections [235].”
GLP‐1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities
Roth, J. D., Erickson, M. R., Chen, S., & Parkes, D. G. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01537.x · Cited by 74
Yu Pan, C., Han, P., Liu, X., Yan, S., Feng, P., Zhou, Z., Lv, X., Tian, H., Jin Kui, Y., Su, B., et al. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2541 · Cited by 71
Novel GLP-1 receptor agonists for diabetes
Garber, A. J. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.638282 · Cited by 69
“In this extended-release formulation, exenatide is incorporated within a matrix of poly-(D,L-lactide-co-glycolide) (PLG), a polymer that degrades slowly over time when injected into the subcutaneous space, resulting in the slow release of the exenatide [46].”
BackgroundLiu, Q., Adams, L., Broyde, A., Fernandez, R., Baron, A. D., & Parkes, D. G. (2010) · Cardiovascular Diabetology · doi:10.1186/1475-2840-9-32 · Cited by 66
Pinelli, N. R., & Hurren, K. M. (2011) · Annals of Pharmacotherapy · doi:10.1345/aph.1q024 · Cited by 59
Mechanisms and clinical efficacy of lixisenatide for the management of type 2 diabetes
Horowitz, M., Rayner, C. K., & Jones, K. L. (2013) · Advances in Therapy · doi:10.1007/s12325-013-0009-4 · Cited by 58
“In some European countries, exenatide is also available as an extended-release formulation, which is given as a once-weekly injection [40].”
BackgroundLong-acting preparations of exenatide
Yuan, W., Cai, Y., Liangming Wei, L., Ma, L., Huang, X., Tao, A., & Liu, Z. (2013) · Drug Design, Development and Therapy · doi:10.2147/dddt.s46970 · Cited by 57
Advances in venom peptide drug discovery: where are we at and where are we heading?
Smallwood, T. B., & Clark, R. J. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1922386 · Cited by 48
“This extends the duration of exenatide release, allowing for the therapeutic levels of the drug to be maintained with weekly injections [11].”
BackgroundFukuda-Tsuru, S., Anabuki, J., Abe, Y., Yoshida, K., & Ishii, S. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.09.024 · Cited by 53
“Long-acting types of GLP-1 mimetics and analogs, which confer resistance to the effect of DPP-4, produce superior clinical glycemic control (Deacon, 2009; Malone et al., 2009).”
BackgroundWerner, U. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2013.06.003 · Cited by 47
An overview of new GLP-1 receptor agonists for type 2 diabetes
Tomlinson, B., Hu, M., Zhang, Y., Chan, P., & Liu, Z.-M. (2016) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2016.1123249 · Cited by 44
Dulaglutide for the treatment of type 2 diabetes
Scheen, A. J. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1296131 · Cited by 49
Trahair, L. G., Horowitz, M., Hausken, T., Feinle-Bisset, C., Rayner, C. K., & Jones, K. L. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2475 · Cited by 37
Bolli, G. B., & Owens, D. R. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12253 · Cited by 36
Unlocking the multifaceted roles of GLP-1: Physiological functions and therapeutic potential
AL-Noshokaty, T. M., Abdelhamid, R., Abdelmaksoud, N. M., Khaled, A., Hossam, M., Ahmed, R., Saber, T., Khaled, S., Elshaer, S. S., & Abulsoud, A. I. (2025) · Toxicology Reports · doi:10.1016/j.toxrep.2025.101895 · Cited by 30
“Few scientific trials have examined EX-LAR for weight loss, and most involve T2D patients [289].”
Tanaka, T., Nangaku, M., & Nishiyama, A. (2011) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e328349af9d · Cited by 28
Pharmacological profile, efficacy and safety of lixisenatide in type 2 diabetes mellitus
Forst, T., & Pfützner, A. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.838559 · Cited by 25
“Exenatide-LAR is composed of microspheres encapsulating the exenatide peptide, and is suitable for once-weekly subcutaneous injection [26].”
BackgroundInvestigational glucagon-like peptide-1 agonists for the treatment of obesity
Tomlinson, B., Hu, M., Zhang, Y., Chan, P., & Liu, Z.-M. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1221925 · Cited by 25
Novel therapeutics and targets for the treatment of diabetes
Aicher, T. D., Boyd, S. A., McVean, M., & Celeste, A. J. (2010) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.10.1 · Cited by 22
Exendins and exendin analogs for diabetic therapy: a patent review (2012-2015)
Park, E. J., Lim, S. M., Lee, K. C., & Na, D. H. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2016.1192130 · Cited by 22
Ueda, T., Ito, T., Tomita, K., Togame, H., Fumoto, M., Asakura, K., Oshima, T., Nishimura, S., & Hanasaki, K. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.06.002 · Cited by 21
Tzefos, M., Harris, K., & Brackett, A. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1q379 · Cited by 21
Combining Basal Insulin Analogs with Glucagon-Like Peptide-1 Mimetics
Perfetti, R. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2010.0250 · Cited by 19
Lixisenatide – A New Glucagon-like Peptide 1 Receptor Agonist in the Treatment of Type 2 Diabetes
Vidal, J. (2010) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2013.09.02.76 · Cited by 15
Herz, H., Song, Y., Ye, Y., Tian, L., Linden, B., Haija, M. A. E., Chu, Y., Grobe, J. L., Lengeling, R. W., & Mokadem, M. (2021) · Nutrients · doi:10.3390/nu14010120 · Cited by 9
“Advancement in our understanding of GLP-1 signaling and its role in glucose metabolism has led to the development of several pharmacologically active GLP-1 receptor agonists, such as liraglutide, exenatide, and semaglutide, for the treatment of type 2 diabetes [14,15,29].”
Polu, P. R. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100686 · Cited by 7
Advances in GLP-1 receptor agonists delivery systems for obesity and diabetes
Abbasi, M., Sun, K., Huggins, K. W., Heath, B., DeLoit, H., McGinness, L., & Mccamy, K. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.01.035 · Cited by 11
Braun, V., Lebouc, V., Schwach, G., & Destruel, P.-L. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.106122 · Cited by 2
Arpaç, B., Pesce, C., Tognetti, F., Fragassi, A., Casagrande, L., Garofalo, M., Salmaso, S., & Caliceti, P. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125686 · Cited by 2
Efficacy and safety of exenatide once weekly: an overview of the DURATION trials
Block, C. D., & van Gaal, L. (2012) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.12.51 · Cited by 3
Derosa, G., & Maffioli, P. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0548-5_18 · Cited by 2
Optimizing glycemic control: clinical utility of exenatide prolonged release injection
Derosa, G., & Maffioli, P. (2012) · Research and Reports in Endocrine Disorders · doi:10.2147/rred.s24237 · Cited by 1
Sitagliptin or exenatide once weekly for type 2 diabetes: comparison of the clinical trials
Doggrell, S. A. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.576671 · Cited by 1
Bilous, F. R., & Donnelly, R. (2010) · doi:10.1002/9781444391374.ch11 · Cited by 1
GLP‐1 Biology, Signaling Mechanisms, Physiology, and Clinical Studies
Burcelin, R., Cabou, C., Magnan, C., & Gourdy, P. (2011) · Wiley eBooks · doi:10.1002/9780470910016.ch11
Ferreira, M. C. (2013) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2013.tde-01112013-113904 · Cited by 3
Farah, L. X. S. (2015) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.5.2015.tde-05102015-114814
Paulo, S., & Girardi, C. (2015)
Aragão, G. C. (2017) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2017.tde-09032017-123135
Exenatide QW – New Perspectives 5 Years after its First Use
Guja, C., & Mihai, A. D. (2017) · Romanian Journal of Diabetes Nutrition and Metabolic Diseases · doi:10.1515/rjdnmd-2017-0033
New pharmacological approaches in type 2 diabetes mellitus
Cusi, K. J. (2009) · Dialnet (Universidad de la Rioja) · doi:10.1016/b978-84-8086-683-5.50016-0
A brief review on newer Glucagon like Peptide-1 analogues
Dharmaraj, B. (2020) · International Journal of Preclinical and Clinical Research · doi:10.51131/ijpccr/v1i1.7
Drugs from Animal Venoms: Overcoming the Challenges to Treat Erectile Dysfunction
de Lima, M. E., & Nunes, K. P. (2022) · Venoms and Toxins · doi:10.2174/2666121702666220425111433
Destruel, P.-L., Braun, V., Lebouc, V., & Schwach, G. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4852929
Synthèse de peptides bioactifs inspirés des venins
Giribaldi, J. (2019) · theses.fr (ABES) · doi:10.70675/4396528bz40f7z47abz935az5799907cf557
Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 1 Diabetes
Buros‐Stein, A., PAULEY, M. E., & Snell‐Bergeon, J. K. (2026) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2026.04.003
Metadata
- Authors
- Malone, J., Trautmann, M., Wilhelm, K., Taylor, K., & Kendall, D. M.
- Affiliations
- Eli Lilly (United States) (US)
- Amylin Pharmaceuticals, Inc., 9360 Towne Centre Drive, San Diego, CA 92121, USA
- International Diabetes Center, 3800 Park Nicollet Blvd, Minneapolis, MN, 55416, USA
- ORCID
- Kendall, David M
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2009-03
- Volume
- 18
- Issue
- 3
- Pages
- 359-367
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W1975612744
- Cited by
- 55
- References
- 55
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 3 · 2023: 1 · 2022: 1 · 2021: 2 · 2020: 2 · 2019: 1 · 2017: 4 · 2016: 3 · 2015: 3 · 2014: 3 · 2013: 6 · 2012: 4
- FWCI
- 5.32
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Investigational Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- exenatide, sustained-release formulation, GLP-1 receptor agonists, type 2 diabetes, glycemic control, weight loss, insulin secretion, glucagon suppression, gastric emptying, drug tolerability
- MeSH terms
- Exenatide, Animals, Clinical Trials as Topic, Diabetes Mellitus, Type 2, Drug Tolerance, Glycated Hemoglobin, Humans, Peptides, Venoms, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.